
Supplementary Material

Figure S1. Schematic presentation of PSO patients' selection




Figure S2. Study flowchart




Table S1. Overview of study drugs characteristics

ATC	Active Substance	Trade Name	Posology	Drug speciality code	Year of Marketing Authorisation	Therapeutic Indications	Reimbursability	Ex Factory Price	Additional Monitoring
D05 Antipsoriatics									
D05BB02	Acitretin	Neotigason	25 mg/20 tablets	027480021	26/04/1997	Severe forms of psoriasis, pustular psoriasis, Severe and refractory forms of dermatitis, Darier's disease lichen planus	A	19,83 €	Additional Monitoring
			10 mg/30 tablets	027480019			A	14,11 €	Additional Monitoring
		Zorias	25 mg/20 tablets	041619065	feb-13		A	12,73 €	Additional Monitoring
			10 mg/30 tablets s	041619014			A	9,06 €	Additional Monitoring
L04 Immunosuppressants									
L04AD01	Cyclosporine	Ciqorin	100 mg/30 tablets	042787299	-	Organ transplantation, Bone marrow transplantation, Endogenous uveitis, Nephrotic syndrome, Rheumatoid arthritis, Psoriasis, Atopic dermatitis	A	€ 29,52	-
			10mg/ 50 tablets	042787251			A	€ 5,42	-
			25mg/ 50 tablets	042787263			A	€ 13,55	-
			50mg/ 50 tablets	042787275			A	€ 26,27	-
			10mg/ 0,2 ml	039153123			29/12/2009	A	€ 17,85
L04AX03	Methotrexato	Reumaflex	12,5mg/0,25ml	039153628	29/12/2009	Rheumatoid arthritis, Juvenile idiopathic arthritis, Severe psoriasis, Crohn's disease	A	€ 18,20	-
			15mg/0,30ml	039153224			A	€ 26,07	-
			17,5mg/0,35ml	039153679			A	€ 25,09	-
			20mg/0,40ml	039153325			A	€ 34,48	-
			25mg/0,50ml	039153426			A	€ 42,34	-

L04AX07	Dimethylfumarate	Skilarence	30 mg/42 tablets	045493018	23/06/2017	Psoriasis plaques	A	94,16 €	-
			120 mg/ 90 tablets	045493044			A	201,78 €	-
L04AA29	Tofacitinib	Xeljanz	50mg/56 tables	045320037	22/03/2017	Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Ulcerative colitis, Juvenile idiopathic arthritis	H	720,92 €	AIFA Note 06/07/2021
			50mg/182 tablets	045320049			H	2.342,83 €	
			50mg/112 tablets	045320102			H	1.441,83 €	
			10mg/112 tablets	045320088			H	2.883,67 €	
			30mg/56 tablets	043867023			A	758,10 €	
L04AA32	Apremilast	Otezla	4 x 10 mg + 4 x 20 mg + 19 x 30 mg tablets	043867011	15/01/2015	Psoriatic arthritis, Psoriasis, Behçet's disease	A	365,51 €	Additional Monitoring
			25mg/0,51ml 4syringes	044691057	14/01/2016	H	314,07 €	Additional Monitoring – AIFA paper form	
Benepali	50mg/1ml 4 syringes	044691018	H	629,00 €					
	50mg/4 syringes	044691020	H	629,00 €					
L04AB01	Etanercept	Erelzi	25mg/0,5ml 4 syringes	045451034	23/06/2017	Rheumatoid arthritis, Juvenile idiopathic arthritis, Psoriatic arthritis, Axial spondyloarthritis, Plaque psoriasis, Paediatric plaque psoriasis	H	299,34 €	Additional Monitoring – AIFA paper form
			50mg/1ml 4 syringes	045451073			H	598,66 €	
		50mg/1ml 4 pens	045451111	H			598,66 €		
		10 mg 1 vial	034675215	H			184,21 €		
		Enbrel	25 mg 4 syringes	034675102	03/02/2000		H	460,51 €	AIFA paper form

		50 mg 1 ml 4 pens	034675191			H	921,08 €		
		25 mg 4 syringes	034675037			H	460,51 €		
		50 mg 4 syringes	034675140			H	921,02 €		
L04AB02	Infliximab	Remicade	100mg 1 vial	034528012	13/08/1999		463,53 €	AIFA paper form - AIFA note 07/03/2022	
		Zessly	100mg 1 vial	046635013	18/05/2018	Rheumatoid arthritis, Crohn's disease, Ulcerative colitis, Ankylosing spondylitis, Psoriatic arthritis, Psoriasis	H	386,28 €	Additional Monitoring –
		Flixabi	100mg 1 vial	044892014	26/05/2016		H	386,28 €	AIFA paper form - AIFA note 07/03/2022
L04AB02	Infliximab	Inflectra	100mg 1 vial	043010014	10/09/2013		386,28 €	AIFA Note 07/03/2022	
			100mg 1 vial	042942019			H	386,28 €	
		Remsima	120mg/ml 1 pen	042942122	22/11/2019	Rheumatoid arthritis, Crohn's disease, Ulcerative colitis, Ankylosing spondylitis, Psoriatic arthritis, Psoriasis	H	288,98 €	AIFA paper form - AIFA note 07/03/2022
			120mg/ml 4 pens	042942146			H	1.155,94 €	
L04AB04	Adalimumab		20mg/0,4ml 1 syringe	045317017			192,87 €		
		Amgevita	40mg/0,8ml 2 pens	045317070	22/03/2017		H	771,50 €	AIFA paper form
			40mg/0,8ml 2 syringes	045317031			H	771,50 €	
L04AB04	Adalimumab		80mg/0,8ml 1 pen	035946209		Rheumatoid arthritis, Juvenile idiopathic arthritis, Axial spondyloarthritis, Psoriatic arthritis, Paediatric plaque psoriasis, Crohn's disease, Ulcerative colitis, Uveitis	H	964,37 €	AIFA paper form
		Humira	80mg/0,8ml 1 syringe	035946197	08/09/2003		H	964,37 €	
			40mg/0,4ml 2 pens	035946161			H	964,37 €	
		Idacio	40mg/0,8ml 1vial	047805015	02/04/2019		H	342,45 €	Additional Monitoring – AIFA paper form

			40mg/0,8ml 2pens	047805039			H	684,71 €	
			40mg/0,8ml 2 syringes	047805027			H	684,71 €	
			40mg/0,4ml 1 pen	049376092			H	342,35 €	Additional Monitoring – AIFA paper form
		Yuflyma	40mg/ 0,4ml 4 pens	049376116	11/02/2021		H	1.369,42 €	
			40mg/0,8ml 2 pens	046889059			H	684,71 €	
			20mg/04ml 2 syringes	046889073	26/07/2018		H	342,35 €	Additional Monitoring – AIFA paper form
		Hyrimoz	40mg/0,8ml 2 pens	046889022			H	684,71 €	
			40mg/0,8ml 2 pens	045616063			H	684,71 €	Additional Monitoring – AIFA paper form
		Imraldi	40mg/0,8ml 2 syringes	045616024	24/08/2017		H	684,71 €	
			200mg/ml 1 syringe	039539085			H	920,55 €	
L04AB05	Certolizumab	Cimzia	200mg/ml 2 pens	039539059	01/10/2009	Rheumatoid arthritis, Axial spondyloarthritis, Ankylosing spondylitis, Psoriasis plaques, Psoriatic arthritis	H	920,55 €	AIFA paper form
			200mg/ml 2 siringhe	039539010			H	920,55 €	
			130 mg 26 ml 1 vial	038936050			H	2.842,88 €	
L04AC05	Ustekinumab	Stelara	45 mg/0,5 ml 1 syringe	038936035	16/01/2009	Psoriasis plaques, Psoriatic arthritis, Crohn's disease, Ulcerative colitis	H	2.842,88 €	AIFA paper form
			90 mg/ml 1 syringe	038936047			H	2.842,88 €	

			45 mg/0,5 ml 1 vial	038936011			H	2.842,88 €	
			150 mg/ml 1 pen	043873049			H	473,81 €	
			300 mg/2 ml pens	043873102			H	947,63 €	
			150 mg/ ml 1 syringe	043873025			H	473,81 €	
L04AC10	Secukinumab	Cosentyx	300 mg/2 ml		15/01/2015	Plaque psoriasis in paediatric patients juvenile idiopathic arthritis, Arthritis related to enthesitis, Juvenile psoriatic arthritis			AIFA paper form
			150 mg/ml 1 syringe	043873088			H	947,63 €	
			150 mg/ ml 2 pens	043873052			H	947,63 €	
			150 mg/ ml 2 syringes	043873037			H	947,63 €	
L04AC12	Brodalumab	Kyntheum	1,5 ml 140 mg/ml 2 syringes	045484019	17/07/2017	Psoriasis plaques	H	1.105,36 €	Additional Monitoring – AIFA paper form
L04AC13	Ixekizumab	Taltz	80/ ml mg 2 pens	044863025	25/04/2016	Psoriasis plaques, Paediatric plaque psoriasis, Psoriatic arthritis, Axial spondylarthritis	H	2.025,40 €	-
			80/ ml mg 2 syringes	044863052			H	2.025,40 €	
L04AC16	Guselkumab	Tremfya	100 mg/ml 1 ml 1 pen	045772023	10/11/2017	Psoriatic arthritis, Psoriasis plaques	H	2.062,98 €	Additional Monitoring – AIFA paper form
			100 mg/ml 1 ml 1 syringe	045772011			H	2.062,98 €	
L04AC17	Tildrakizumab	Ilumetri	100mg/ml	047196011	17/09/2018	Psoriasis plaques	H	3.118,45 €	Additional Monitoring – AIFA paper form
L04AC18	Risankizumab	Skyrizi	75 mg/0,83 ml	047821018	26/04/2019	Psoriatic arthritis, Psoriasis plaques	H	3.230,00 €	Additional Monitoring – AIFA paper form

L04AA56	Deucravacitinib	-	-	-	-	Psoriatic arthritis, Psoriasis plaques	Not commercially available	-	-
L04AC21	Bimekizumab	Bimzelx	160mg/ml	-	-	Psoriasis plaques	CNN	-	Additional Monitoring – AIFA paper form
L04AC21	Spesolimab	Spevigo	450 mg	050464015	-	Psoriasis pustularis	CNN	-	-

Abbreviations: A: essential drugs and those for chronic diseases, fully reimbursed by the National Health Service (NHS); H: drugs for hospital use only that can be used only in hospitals and/or provided in the context of hospitals and assimilated facilities; CNN: band c, non-negotiated; Aifa notes: regulatory instrument that defines the therapeutic indications for which a particular drug is reimbursable under the NHS; Additional Monitoring: Medicines subject to close and specific monitoring by regulatory agencies.

Table S2. Description of induction and maintenance phases of PSO pharmacology therapy

ATC V	Active Substance	Drug speciality	Drug speciality Description	Package Days	Induction Posology Description	Maintenance Posology Description			
L04AA32	Apremilast	043867011	4cpr x 10mg	14	1 tablet 10mg daily 1, 2 tablets 10mg daily 2, 1 tablet 10mg and 1 tablet 20mg daily 3, 2 tablets 20mg daily 4, 1 tablet 20mg and 1 tablet 30mg daily 5, 2 tablets 30mg daily for 9 days	-			
			4cpr x 20mg		-				
		19cpr x 30mg tablets	-						
		043867023	30 mg 56 tablets		-	-	2 tablets every day for as long as the Therapeutic Plan is valid		
		L04AB01	Etanercept		04675052	50mg/1ml	14	2 x 50mg syringes every 7 days for 84 days	1 x 50 mg syringe every 7 days for as long as the Therapeutic Plan lasts
						4 syringes		-	
					034675013	50mg/1ml	14	2 x 50mg syringes every 7 days for 84 days	1 x 50 mg syringe every 7 days for as long as the Therapeutic Plan lasts
						4 syringes		-	
					034675037	25mg/1ml	7	2 x 50mg syringes every 7 days for 84 days	1 x 50 mg syringe every 7 days for as long as the Therapeutic Plan lasts
						4 syringes		-	
034675102	25mg/0,5ml			7	2 x 50mg syringes every 7 days for 84 days	1 x 50 mg syringe every 7 days for as long as the Therapeutic Plan lasts			
	4 syringes				-				
034675140	50mg/1ml	14	2 x 50mg syringes every 7 days for 84 days	1 x 50 mg syringe every 7 days for as long as the Therapeutic Plan lasts					
	4 syringes		-						
034675191	50mg/1ml	14	2 pens of 50mg every 7 days for 84 days	1 pen of 50 mg every 7 days for as long as the Therapeutic Plan lasts					
	4 pens		-						
044691020	50mg/1ml	14	2 pens of 50mg every 7 days for 84 days	1 pen of 50 mg every 7 days for as long as the Therapeutic Plan lasts					
	4 pens		-						
Etanercept Biosimilare	044691018	50mg/1ml	14	2 x 50mg syringes every 7 days for 84 days	1 x 50 mg syringe every 7 days for as long as the Therapeutic Plan lasts				
		4 syringes		-					
044691057	50mg/1ml	14	2 x 50mg syringes every 7 days for 84 days	1 x 50 mg syringe every 7 days for as long as the Therapeutic Plan lasts					
	4 syringes		-						

L04AB04	Adalimumab	035946019	40mg/0,8ml 2 syringes	11	2 syringes of 40mg on the first day and 1 syringe after 7 day	1 syringe every 14 days for as long as the Therapeutic Plan is valid
		035946209	80mg/0,8ml 1 pen	7	2 pens of 40mg on the first day and 1 pen after 7 day	1 pen every 14 days for as long as the Therapeutic Plan is valid
		035946033	40mg/0,8ml 2 syringes	11	2 syringes of 40mg on the first day and 1 syringe after 7 day	1 syringe every 14 days for as long as the Therapeutic Plan is valid
		035946084	40mg/0,8ml 2 pens	11	2 pens of 40mg on the first day and 1 pen after 7 days	1 pen every 14 days for as long as the Therapeutic Plan is valid
		035946122	40mg/0,4ml 2 syringes	11	2 syringes of 40mg on the first day and 1 syringe after 7 day	1 syringe every 14 days for as long as the Therapeutic Plan is valid
	035946161	40mg/0,4ml 2 pens	11	2 pens of 40mg on the first day and 1 pen after 7 days	1 pen every 14 days for as long as the Therapeutic Plan is valid	
	Adalimumab Biosimilare	045317031	40mg/0,8ml 2 syringes	11	2 syringes of 40mg on the first day and 1 syringe after 7 day	1 syringe every 14 days for as long as the Therapeutic Plan is valid
		046889022	40mg/0,8ml 2 pens	11	2 pens of 40mg on the first day and 1 pen after 7 days	1 pen every 14 days for as long as the Therapeutic Plan is valid
		047805027	40mg/0,8ml 2 syringes	11	2 syringes of 40mg on the first day and 1 syringe after 7 day	1 syringe every 14 days for as long as the Therapeutic Plan is valid
		045616024	40mg/0,8ml 2 syringes	11	2 syringes of 40mg on the first day and 1 syringe after 7 day	1 syringe every 14 days for as long as the Therapeutic Plan is valid
L04AB05	Certolizumab	039539010	200mg/ml 2 syringes	14	2 syringes every 14 days for 42 days	1 syringe every 14 days for as long as the Therapeutic Plan lasts
		039539059	200mg/ml 2 pens	14	2 pens every 14 days for 42 days	1 syringe every 14 days for as long as the Therapeutic Plan lasts
L04AC05	Ustekinumab*	038936023	90mg/ml 1 vial	28	1 injection every 28 days for 56 days	1 injection every 84 days for as long as the Therapeutic Plan lasts
		038936011	45mg/0,5ml 1 vial	28	1 injection every 28 days for 56 days	1 injection every 84 days for as long as the Therapeutic Plan lasts
		038936035	45mg/0,5ml 1 syringe	28	1 syringe every 28 days for 56 days	1 syringe every 84 days for as long as the Therapeutic Plan lasts
		038936047	90mg/ml 1 syringe	28	1 syringe every 28 days for 56 days	1 syringe every 84 days for as long as the Therapeutic Plan lasts

L04AC10	Secukinumab	043873025	150mg/ml 1 syringe	4	2 syringes every 7 days for 35 days	2 syringes every 28 days for as long as the Therapeutic Plan lasts
		043873102	300mg/2ml 1 pen	7	1 pens every 7 days for 35 days	1 pen every 28 days for as long as the Therapeutic Plan lasts
		043873037	150mg/ml 2 syringes	7	2 syringes every 7 days for 35 days	2 syringes every 28 days for as long as the Therapeutic Plan lasts
		043873049	150mg/ml 1 pen	4	2 pens every 7 days for 35 days	2 pens every 28 days for as long as the Therapeutic Plan lasts
		043873052	150mg/ml 2 pens	7	2 pens every 7 days for 35 days	2 pens every 28 days for as long as the Therapeutic Plan lasts
L04AC12	Brodalumab	045484019	210mg 2 syringes	18	1 syringe every 7 days for 21 days	1 syringe every 14 days for as long as the Therapeutic Plan lasts
L04AC13	Ixekizumab	044863025	80mg/ml 2 syringes	25	2 syringes every 14 days and 1 syringe every 14 days for 84 days	1 syringe every 28 days for as long as the Therapeutic Plan lasts
		044863052	80mg/ml 2 syringes	25	2 syringes every 14 days and 1 syringe every 14 days for 84 days	1 syringe every 28 days for as long as the Therapeutic Plan lasts
		044863013	80mg/ml 1 pen	13	2 pens every 14 days and 1 syringe every 14 days for 84 days	1 pen every 28 days for as long as the Therapeutic Plan lasts
L04AC16	Guselkumab	045772011	100mg/l 1 syringe	28	1 syringe every 28 days for 56 days	1 syringe every 56 days for as long as the Therapeutic Plan lasts
L04AC17	Tildrakizumab	047196011	100mg/ml 1 syringe	28	1 syringe every 28 days for 56 days	1 syringe every 84 days for as long as the Therapeutic Plan lasts
L04AC18	Risankizumab	047821018	75mg/0,83ml 2 syringes	28	2 syringes every 28 days for 56 days	2 syringes every 84 days for as long as the Therapeutic Plan lasts

* ustekinumab 45 mg if body weight is between 60 kg and 100 kg, ustekinumab 90 mg if weight > 100

Table S3. Switch and Swap therapy among drug classes for PSO treatment

		Anti- PDE4	Anti TNF- α				Anti IL-12/23	Anti IL-17			Anti IL-23		
		Apremilast	Etanercept	Infliximab	Adalimumab	Certolizumab	Ustekinumab	Secukinumab	Brodalumab	Ixekizumab	Guselkumab	Tildrakizumab	Risankizumab
Anti- PDE4	Apremilast		Swap	Swap	Swap	Swap	Swap	Swap	Swap	Swap	Swap	Swap	Swap
Anti TNF- α	Etanercept	Swap		Switch	Switch	Switch	Swap	Swap	Swap	Swap	Swap	Swap	Swap
	Infliximab	Swap	Switch		Switch	Switch	Swap	Swap	Swap	Swap	Swap	Swap	Swap
	Adalimumab	Swap	Switch	Switch		Switch	Swap	Swap	Swap	Swap	Swap	Swap	Swap
	Certolizumab	Swap	Switch	Switch	Switch		Swap	Swap	Swap	Swap	Swap	Swap	Swap
Anti IL-12/23	Ustekinumab	Swap	Swap	Swap	Swap	Swap		Swap	Swap	Swap	Swap	Swap	Swap
Anti IL-17	Secukinumab	Swap	Swap	Swap	Swap	Swap	Swap		Switch	Switch	Swap	Swap	Swap
	Brodalumab	Swap	Swap	Swap	Swap	Swap	Swap	Switch		Switch	Swap	Swap	Swap
	Ixekizumab	Swap	Swap	Swap	Swap	Swap	Swap	Switch	Switch		Swap	Swap	Swap
Anti IL-23	Guselkumab	Swap	Swap	Swap	Swap	Swap	Swap	Swap	Swap	Swap		Switch	Switch
	Tildrakizumab	Swap	Swap	Swap	Swap	Swap	Swap	Swap	Swap	Swap	Switch		Switch
	Risankizumab	Swap	Swap	Swap	Swap	Swap	Swap	Swap	Swap	Swap	Switch	Switch	

Legend			
Indicator	Drug class	Swap	Switch
▲	Anti- PDE4	▲	▲
▲	Anti TNF- α	▲	▲
▲	Anti IL-12/23	▲	▲
▲	Anti IL-17	▲	▲

Table S4. Pattern swaps and switches between drugs for the treatment of psoriasis

		Overall	Anti- PDE4	Anti TNF- α		Anti IL-12/23	Anti IL-17		
			Apremilast	Etanercept	Adalimumab	Ustekinumab	Secukinumab	Brodalumab	Ixekizumab
Anti- PDE4	Apremilast	165	141	4	1	4	3	1	10
Anti TNF- α	Etanercept	56	2	37	1	8	5		3
	Infliximab	1							
	Adalimumab	132	1	2	114	4	5		5
	Certolizumab	9	1				1		2
Anti IL-12/23	Ustekinumab	124	3	1	3	109			7
Anti IL-17	Secukinumab	183	4		3	4	161		5
	Brodalumab	0						0	
	Ixekizumab	141		1	2	4	2		128

Legend			
Indicator	Drug class	Swap	Switch
▲	Anti- PDE4	▲	▲
▲	Anti TNF- α	▲	▲
▲	Anti IL-12/23	▲	▲
▲	Anti IL-17	▲	▲

Figure S3. One year medication persistence rates to PSO treatments (30 days gap)




Figure S4. One year medication persistence rates to PSO treatments (90 days gap)

